AI Predicts Heart Failure from ECGs 03/06/26

Welcome to Cardiology Today – Recorded March 06, 2026. This episode summarizes 5 key cardiology studies on topics like breast cancer and cardiac myosin inhibitor. Key takeaway: AI Predicts Heart Failure from ECGs. Article Links: Article 1: Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. (Journal of the American College of Cardiology) Article 2: Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis. (Journal of the American College of Cardiology) Article 3: Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. (Journal of the American College of Cardiology) Article 4: Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. (European heart journal) Article 5: Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-ecgs-03-06-26/ Featured Articles Article 1: Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41493295 Summary: Aficamten, a cardiac myosin inhibitor, was significantly more effective than metoprolol at improving exercise tolerance in patients with obstructive hypertrophic cardiomyopathy. The MAPLE-HCM trial, a head-to-head, international, double-blind, randomized study, demonstrated this definitive finding. Aficamten showed clear superiority over metoprolol in this patient population. Article 2: Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41493294 Summary: Artificial intelligence applied to electrocardiograms enhances the prediction of incident heart failure beyond clinical risk estimation using the PREVENT-Heart Failure equation. This electrocardiogram-artificial intelligence was specifically designed to detect both systolic and diastolic dysfunction. The pooled cohort analysis found that this scalable approach improves identification of individuals at risk for heart failure. Article 3: Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41348072 Summary: The MAPLE-HCM trial demonstrated that aficamten monotherapy provided greater improvement in exercise capacity and multiple secondary endpoints compared to metoprolol monotherapy. This multidomain, patient-level analysis further evaluated aficamten’s effects across various clinically relevant and patient-centric measures of disease burden in obstructive hypertrophic cardiomyopathy. Aficamten definitively improved outcomes compared to the traditional beta-blocker therapy. Article 4: Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41784225 Summary: This study found that nuclear argonaute two exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. This mechanism contributes to cardiac dysfunction, particularly in contexts of high-fat diet. The research demonstrated a causal role for nuclear argonaute two in inducing this specific type of heart failure. These findings offer a novel understanding of disease progression for heart failure with preserved ejection fraction. Article 5: Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41780910 Summary: Breast tumor-secreted A. D. A. M. ten mediates atrial fibrogenesis and fibrillation. This study found that breast cancer itself, independent of treatment-related cardiotoxicity, directly induces atrial fibrillation through this specific molecular mechanism. A retrospective analysis of 1224 female breast cancer patients before therapy and 18159 healthy female participants established this link. This research identifies a direct pathological connection between breast tumors and the development of atrial fibrillation. Transcript Today’s date is March 06, 2026. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. Aficamten, a cardiac myosin inhibitor, was significantly more effective than metoprolol at improving exercise tolerance in patients with obstructive hypertrophic cardiomyopathy. The MAPLE-HCM trial, a head-to-head, international, double-blind, randomized study, demonstrated this definitive finding. Aficamten showed clear superiority over metoprolol in this patient population. Article number two. Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis. Artificial intelligence applied to electrocardiograms enhances the prediction of incident heart failure beyond clinical risk estimation using the PREVENT-Heart Failure equation. This electrocardiogram-artificial intelligence was specifically designed to detect both systolic and diastolic dysfunction. The pooled cohort analysis found that this scalable approach improves identification of individuals at risk for heart failure. Article number three. Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. The MAPLE-HCM trial demonstrated that aficamten monotherapy provided greater improvement in exercise capacity and multiple secondary endpoints compared to metoprolol monotherapy. This multidomain, patient-level analysis further evaluated aficamten’s effects across various clinically relevant and patient-centric measures of disease burden in obstructive hypertrophic cardiomyopathy. Aficamten definitively improved outcomes compared to the traditional beta-blocker therapy. Article number four. Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. This study found that nuclear argonaute two exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. This mechanism contributes to cardiac dysfunction, particularly in contexts of high-fat diet. The research demonstrated a causal role for nuclear argonaute two in inducing this specific type of heart failure. These findings offer a novel understanding of disease progression for heart failure with preserved ejection fraction. Article number five. Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation. Breast tumor-secreted A. D. A. M. ten mediates atrial fibrogenesis and fibrillation. This study found that breast cancer itself, independent of treatment-related cardiotoxicity, directly induces atrial fibrillation through this specific molecular mechanism. A retrospective analysis of 1224 female breast cancer patients before therapy and 18159 healthy female participants established this link. This research identifies a direct pathological connection between breast tumors and the development of atrial fibrillation. Thank you for listening. Don’t forget to subscribe. Keywords breast cancer, cardiac myosin inhibitor, artificial intelligence, electrocardiogram, heart failure prediction, metoprolol, atrial fibrillation, high-fat diet, exercise capacity, obstructive hypertrophic cardiomyopathy, nuclear argonaute two, atrial fibrogenesis, diastolic dysfunction, aficamten, cardiac dysfunction, metoprolol monotherapy, exercise tolerance, aficamten monotherapy, tumor-secreted factors, patient-centric measures, systolic dysfunction, myocardial ketogenesis, A. D. A. M. ten, heart failure with preserved ejection fraction. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post AI Predicts Heart Failure from ECGs 03/06/26 first appeared on Cardiology Today.